CT habitat and peritumoral radiomics for predicting progression after repeat TACE in hepatocellular carcinoma: a multicenter study

Abstract

Background This study developed and validated an machine-learning-based radiomics model integrating tumor habitat radiomics, peritumoral radiomics, and clinical features to predict progression-free survival (PFS) following repeat transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Methods This retrospective multicenter study included 270 patients with HCC. Patients from Center 1 were assigned to training (n = 94) and internal validation (n = 41) cohorts, while Centers 2 (n = 82) and 3 (n = 53) served as external validation cohorts. Tumor habitats and 5-mm peritumoral regions were generated from contrast-enhanced CT images. Radiomics features were selected using univariate Cox and LASSO-Cox regression. A fusion model and HPC risk score were constructed by integrating selected radiomics signatures and clinical variables. Performance was assessed using time-dependent ROC, C-index, calibration, decision curve analysis, and Kaplan–Meier analyses. Results The optimal habitat cluster number was K = 2. Eleven habitat features, three peritumoral features, and alpha-fetoprotein were retained in the fusion model. The model achieved AUCs of 0.923, 0.921, and 0.897 for 3-, 6-, and 9-month progression-free survival in the training cohort, and 0.932, 0.863, and 0.916 in the internal validation cohort, respectively; all external AUCs exceeded 0.82. The fusion model showed higher C-index values than the clinical model across cohorts. High-risk patients had significantly shorter PFS than low-risk patients (all P < 0.001). Calibration and decision curve analyses demonstrated good agreement and clinical utility. Conclusion The CT-based fusion model and HPC risk score effectively predicted progression risk in HCC.